Tag Directory / FDA     showing 21–40 of 47



FDA to reassess the safety of BHA, a preservative used in popular snack foods / ABC News

go - Federal health officials will reassess the safety of a chemical called BHA used in foods including potato chips, cereals, frozen meals and meat products

#healthcare #publichealth #governmentpolicy #fda #foodsafety


Saturday, February 14, 2026, 1:21 am / permalink 19176 / 4 stories in 25 days


BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 25 days


FDA refuses to review Moderna flu vaccine / Beckers

Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Wednesday, February 11, 2026, 10:25 am / permalink 19026 / 15 stories in 28 days


AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo / Endpoints

Anna Brown / endpoints - The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Monday, February 9, 2026, 12:21 am / permalink 18917 / 5 stories in 4 wks


Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade / Calgary Sun

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, January 31, 2026, 2:22 pm / permalink 18622 / 9 stories in 5 wks


FDA lifts hold on one of two Phase 3 gene editing studies by Intellia / Endpoints

Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Saturday, January 31, 2026, 7:22 am / permalink 18610 / 4 stories in 5 wks


Oregon baby is still battling infant botulism after ByHeart formula exposure / ABC News

go - A Portland, Oregon, baby got sick with infant botulism after drinking contaminated ByHeart formula donated through a program that helps poor and homeless families

#healthcare #publichealth #governmentpolicy #fda #cdc #foodsafety #infanthealth


Saturday, January 24, 2026, 7:21 pm / permalink 18380 / 7 stories in 6 wks


F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds / NYT

Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda


Saturday, January 17, 2026, 8:21 am / permalink 18126 / 5 stories in 7 wks


FDA rejects cancer therapy for rare post-transplant disease / Beckers

Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 7 wks


FDA moves to remove suicide warnings from GLP-1 weight loss drugs / Medical Express

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #governmentpolicy #fda


Thursday, January 15, 2026, 1:23 pm / permalink 17924 / 8 stories in 7 wks


Nestlé recalls baby formula over toxin risk / Medical Express

medicalxpress - Nestlé has announced a global recall of some baby formula products, saying they may contain a toxin that can cause food poisoning in infants.

#healthcare #publichealth #fda #cdc #foodsafety #productrecall #infanthealth


Saturday, January 10, 2026, 12:22 am / permalink 17716 / 2 stories in 2 months


OpenAI Launches ChatGPT Health: 5 Things to Know / MedCity

Katie Adams / medcitynews - OpenAI announced a new dedicated platform for health conversations. The company said the new offering is not intended for medical diagnosis or treatment — but rather to provide support for personal health navigation.The post OpenAI Launches ChatGPT Health…

#healthcare #publichealth #governmentpolicy #fda


Wednesday, January 7, 2026, 6:23 pm / permalink 17617 / 21 stories in 2 months


FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints

Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months


Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight / Medical Express

medicalxpress - Many consumers feel pride in avoiding the glazed pastries in the supermarket and instead opting for "all natural" granola that comes packed with extra protein. Same goes for low-fat yogurts "made with real fruit," "organic" plant-based milks and bottled "…

#obesity #healthcare #weightloss #publichealth #fda


Monday, December 29, 2025, 1:21 am / permalink 17332 / 7 stories in 2 months


Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss / MedCity

Frank Vinluan / medcitynews - Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #drugdevelopment #fda


Tuesday, December 23, 2025, 3:22 pm / permalink 17254 / 36 stories in 2 months


FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer / OncoDaily

oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Saturday, December 20, 2025, 9:20 pm / permalink 17185 / 13 stories in 2 months


FDA Removes Key Limitation on the Use of Real-World Evidence in Regulatory Reviews / OncoDaily

oncodaily - On December 15, 2025, the U.S. Food and Drug Administration (FDA) announced a significant update to its regulatory approach regarding the use of real-world evidence (RWE) in drug and medical […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda


Saturday, December 20, 2025, 4:21 pm / permalink 17179 / 13 stories in 2 months


FDA approves 1st gene therapy for Wiskott-Aldrich syndrome / Beckers

Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Monday, December 15, 2025, 2:21 am / permalink 16954 / 4 stories in 2 months


A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes / Fierce

fiercehealthcare - Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from 12 former commissioners of the agency.

#healthcare #publichealth #governmentpolicy #biotech #drugdevelopment #fda #vaccinesafety


Thursday, December 4, 2025, 10:23 am / permalink 16565 / 10 stories in 3 months


FDA approves all ages gene therapy for spinal condition / Beckers

Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda


Monday, December 1, 2025, 4:21 am / permalink 16428 / 2 stories in 3 months


Back to Top


FDA Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.